| FDA report questions efficacy of Pfizer's kidney cancer drug Inlyta - PMLiVE |
|
|
PMLiVE Inlyta is due for review by the FDA's Oncologic Drugs Advisory Committee (ODAC) on December 7 as a second-line treatment for patients with advanced renal cell carcinoma, based on the results of a single efficacy study in 723 patients which compared |